Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IOS-1002 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- ImmunOs Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
IOS-1002 + pembrolizumab is an investigational combination therapy for advanced solid tumors. IOS-1002 is a first-in-class, HLA-based checkpoint inhibitor developed by ImmunOs Therapeutics that targets the immune inhibitory receptors LILRB1 (ILT2), LILRB2 (ILT4), and KIR3DL1 on innate and adaptive immune cells. By blocking these receptors, IOS-1002 enhances anti-tumor immunity by promoting infiltration of M1 macrophages, T cells, and NK cells into the tumor microenvironment[5][1][2]. Pembrolizumab (Keytruda) is a humanized monoclonal antibody that inhibits PD-1 on lymphocytes to prevent cancer-mediated immune evasion[6]. The combination aims to synergistically enhance anti-tumor responses in patients with advanced solid tumors who may not respond adequately to single-agent immunotherapy. This regimen is currently being evaluated in phase 1 clinical trials as both monotherapy and combination therapy[3][4].
- Other names
- pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)KIR3DL1 (Killer cell immunoglobulin-like receptor 3DL1)
Beyond the preview
Go deeper on IOS-1002 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IOS-1002 + pembrolizumab.